Nature publishes results from pre-clinical research and phase 1b study of Aducanumab
Biogen announced that results from pre-clinical research and PRIME, the Phase 1b study of its investigational treatment for early Alzheimer’s disease, aducanumab, were published in Nature. Aducanumab is currently being evaluated by Biogen in two global Phase 3 studies. August 31, 2016